<DOC>
	<DOCNO>NCT01083849</DOCNO>
	<brief_summary>The purpose study obtain data safety effectiveness ZemplarÂ® ( paricalcitol ) injection paricalcitol capsule real-life clinical practice . Participants , treat paricalcitol in-label everyday setting , include study . A period 12 month choose order also obtain experience maintenance dose treatment optimization paricalcitol injection paricalcitol capsule long-term use .</brief_summary>
	<brief_title>Long-Term Therapy Outcomes When Treating Chronic Kidney Disease ( CKD ) Patients With Paricalcitol German Austrian Clinical Practice</brief_title>
	<detailed_description>According protocol amendment 16 October 2010 Austria participate study . Paricalcitol injection ( intravenous ( IV ) therapy ) approve Germany December 2004 Austria June 2003 prevention treatment secondary hyperparathyroidism participant need dialysis . In April 2008 Germany January 2008 Austria , paricalcitol capsule ( oral use ( p.o . ) ) launch prevention treatment secondary hyperparathyroidism individual Chronic Kidney Disease stage 3 - 5 ( i.e. , predialysis dialysis ) , thus enable early treatment participant chronic kidney disease reach stage require dialysis . Postmarketing observational study well-planned study design , define study protocol biometrical estimate necessary profound understand effectiveness adverse drug reaction , especially unknown rare . Accordingly , purpose study obtain data safety effectiveness paricalcitol injection capsule real-life clinical practice . In study , paricalcitol prescribe on-label basis everyday setting . A period 12 month consciously choose order also obtain experience maintenance dose treatment optimization paricalcitol injection paricalcitol capsule long-term use .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>The inclusion criterion base Summary Product Characteristics paricalcitol injection capsule : Prevention therapy secondary hyperparathyroidism presence chronic kidney disease Patients treat paricalcitol least 6 month prior inclusion study The contraindication list Summary Product Characteristics paricalcitol injection capsule apply An additional exclusion criterion parathyroid hormone value &gt; 1000 pg/mL ( may sign tertiary hyperparathyroidism ) exist treatment paricalcitol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Observational study</keyword>
	<keyword>Paricalcitol</keyword>
	<keyword>Treatment Hyperparathyroidism</keyword>
	<keyword>Chronic kidney disease stage 3 , 4 5 ( CKD stage 3 , 4 5 )</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Zemplar</keyword>
	<keyword>sHPT</keyword>
	<keyword>Secondary</keyword>
</DOC>